Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment
Abstract Atezolizumab, a biotherapeutic monoclonal antibody directed against PD-L1, has been shown to be efficacious in multiple oncology indications. In clinical trials, a subset of patients developed anti-atezolizumab antibodies, necessitating the development of a neutralizing antibody (NAb) assay...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-02-01
|
| Series: | AAPS Open |
| Online Access: | https://doi.org/10.1186/s41120-024-00105-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|